Investigating the impact of EU legislation
Dr. Mark W Lowdell
University College London, UK
Dr Mark W Lowdell PhD, FRCPath is a senior lecturer / assistant professor in the Department of Haematology of University College London Medical School and Director of the Paul O’Gorman Laboratory of Cellular Therapeutics. He is an Honorary Consultant Scientist and Director of Cellular Therapy at Royal Free Hampstead NHS Trust.
Dr Lowdell trained as an immunopathologist at the Royal London Hospital and moved to the Royal Free Hospital / UCL in 1994 to set up the immunotherapy programme in malignant haematology. He has specialist knowledge of cellular therapeutics and is the UK representative on the Joint Accreditation Committee ISCT/EBMT (JACIE) which is responsible for setting and co-ordinating standards for cellular therapies across Europe. He holds Qualified Person status for the release of investigational somatic cell therapy medicinal products in the EU and is a Designated Individual under a Human Tissue Authority licence for therapeutic cells.
Dr Lowdell’s expertise in the field of cell therapy has led to numerous appointments to academic, government and industrial advisory boards. Most recently he has sat on the Irish Health Research Board “Patient directed research panel”, the Import/Export Working Party of the UK Human Tissue Authority, acted as an advisor in ATMP manufacture to the Health Sciences Agency of Singapore and is a member of the scientific advisory board of Cell Medica in the UK and Coronado Bioscience in the US, SMEs commercialising adoptive cell therapies.
The team at RFH/UCL led by Dr Lowdell includes 9 GMP production scientists and 7 pre-clinical research scientists. The group is extremely adept at translating basic science into GMP compliant products, most recently working with the cardiothoracic and upper airways surgeons to produce a GMP-compliant recelluarised autologous/allogeneic trachaea for transplantation in a child at Great Ormond Street Children’s Hospital. He is part of the multi-disciplinary UCL regenerative medicine group working on complex 3-D tissue restructuring.